{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:02:01Z","timestamp":1787022121496,"version":"build-2736575974"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The study aims to examine the extent to which the updated ACC\/AHA management of blood cholesterol guideline (2018) is implemented in practice and to assess the value of the clinical pharmacist interventions in improving physicians\u2019 adherence the guidelines recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We utilized in this study an interventional before-after design. The study was conducted on 272 adult patients who visited the study site internal medicine clinics and were candidates for statin therapy based on the 2018 ACC\/AHA guidelines for cholesterol management. Adherence to guideline recommendations was measured before and after clinical pharmacists\u2019 interventions by calculating the percentage of patients receiving statin therapy as per guideline recommendation, the type and intensity (moderate or high intensity) of statin therapy used, and the need for additional non-statin therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adherence with guideline recommendations was significantly improved from 60.3% to 92.6% (X2 = 79.1, p = 0.0001) after clinical pharmacist interventions. Among patients who were on statin therapy, the percentage of those who were on proper statin intensity increased significantly from 47.6% to 94.4% (X2 = 72.5, p = 0.0001). The combination of statins with non-statin therapies such as ezetimibe and PCSK9 inhibitors increased from 8.5% to 30.6% (X2 = 95, p&lt;0.0001) and from 0.0% to 1.6% (X2 = 6, p = 0.014), respectively. The use of other lipid-lowering agents was diminished from 14.6% to 3.2% (X2 = 19.2, p&lt;0.0001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Collaboration between physicians and clinical pharmacists is a crucial strategy to improve patients\u2019 treatment and hence, achieve better health outcomes among patients suffering from dyslipidemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0283369","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:29:48Z","timestamp":1679923788000},"page":"e0283369","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Value of the clinical pharmacist interventions in the application of the American College of Cardiology (ACC\/AHA) 2018 guideline for cholesterol management"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0344-4056","authenticated-orcid":true,"given":"Mohammad M.","family":"AlAhmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"ZainAlAbdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khozama","family":"AlAhmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqbal","family":"AlAhmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah","family":"AbuRuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"pone.0283369.ref001","first-page":"e153","article-title":"Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association","volume":"145","author":"CW Tsao","year":"2022","journal-title":"Circulation"},{"key":"pone.0283369.ref002","author":"World Health Organization (WHO).","year":"2021"},{"key":"pone.0283369.ref003","doi-asserted-by":"crossref","first-page":"559751","DOI":"10.3389\/fpubh.2021.559751","article-title":"Global, Regional, and National Death, and Disability-Adjusted Life-Years (DALYs) for Cardiovascular Disease in 2017 and Trends and Risk Analysis From 1990 to 2017 Using the Global Burden of Disease Study and Implications for Prevention.","volume":"9","author":"Z Li","journal-title":"Front Public Health"},{"key":"pone.0283369.ref004","doi-asserted-by":"crossref","first-page":"e031969","DOI":"10.1136\/bmjopen-2019-031969","article-title":"Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population-based study","volume":"9","author":"I Mahmoud","year":"2019","journal-title":"BMJ Open"},{"key":"pone.0283369.ref005","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13098-017-0287-0","article-title":"Prevalence of overweight and obesity in United Arab Emirates Expatriates: the UAE National Diabetes and Lifestyle Study","volume":"9","author":"N Sulaiman","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"pone.0283369.ref006","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"NJ Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"pone.0283369.ref007","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.jacc.2018.11.004","article-title":"Systematic Review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"PWF Wilson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"pone.0283369.ref008","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamacardio.2019.0911","article-title":"2018 American Heart Association\/American College of Cardiology\/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention","volume":"4","author":"SM Grundy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"pone.0283369.ref009","article-title":"LDL-C target attainment in secondary prevention of ASCVD in the United States: barriers, consequences of nonachievement, and strategies to reach goals","author":"J Underberg","year":"2022","journal-title":"Postgraduate Medicine."},{"key":"pone.0283369.ref010","first-page":"1","article-title":"Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany","author":"AK Gitt","year":"2022","journal-title":"Clinical Research in Cardiology"},{"key":"pone.0283369.ref011","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"DC Goff","year":"2014","journal-title":"Circulation"},{"key":"pone.0283369.ref012","article-title":"Statin non-adherence: clinical consequences and proposed solutions","author":"RS Rosenson","year":"2016","journal-title":"F1000Res 5."},{"key":"pone.0283369.ref013","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.jacc.2015.02.083","article-title":"Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution","volume":"65","author":"PV Nguyen","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"pone.0283369.ref014","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1001\/archinte.162.10.1149","article-title":"A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).","volume":"162","author":"RT Tsuyuki","year":"2002","journal-title":"Arch Intern Med"},{"key":"pone.0283369.ref015","article-title":"Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction","volume":"4","author":"H Yun","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"pone.0283369.ref016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archinternmed.2011.399","article-title":"Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials","volume":"171","author":"V Santschi","year":"2011","journal-title":"Arch Intern Med"},{"key":"pone.0283369.ref017","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1345\/aph.1K618","article-title":"Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management","volume":"42","author":"M Machado","year":"2008","journal-title":"Ann Pharmacother"},{"key":"pone.0283369.ref018","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4066\/AMJ.2011.698","article-title":"The roles of community pharmacists in cardiovascular disease prevention and management","volume":"4","author":"J George","year":"2011","journal-title":"Australas Med J"},{"key":"pone.0283369.ref019","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2015.09.025","article-title":"The role of the clinical pharmacist in the care of patients with cardiovascular disease","volume":"66","author":"SP Dunn","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"pone.0283369.ref020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00210-016-1252-4","article-title":"Pleiotropic effects of statins: new therapeutic targets in drug design","volume":"389","author":"O Bedi","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"pone.0283369.ref021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10157-016-1286-4","article-title":"Pleiotropic effects of statins on acute kidney injury: involvement of Kruppel-like factor 4","volume":"21","author":"T Yoshida","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"pone.0283369.ref022","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/1570161116666180723120608","article-title":"Pleiotropic Effects of Statins: Untapped Potential for Statin Pharmacotherapy","volume":"17","author":"S Mohammad","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"pone.0283369.ref023","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1592\/phco.20.17.1375.34895","article-title":"Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals","volume":"20","author":"M Bozovich","year":"2000","journal-title":"Pharmacotherapy"},{"key":"pone.0283369.ref024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11096-011-9479-0","article-title":"The role of clinical pharmacist on lipid control in dyslipidemic patients in North of Jordan.","volume":"33","author":"L Tahaineh","year":"2011","journal-title":"Int J Clin Pharm"},{"key":"pone.0283369.ref025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1715163516662291","article-title":"A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study).","volume":"149","author":"RT Tsuyuki","year":"2016","journal-title":"Can Pharm J (Ott)"},{"key":"pone.0283369.ref026","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/j.japh.2017.03.002","article-title":"Prescriber acceptance rate of pharmacists\u2019 recommendations","volume":"57","author":"JF Doellner","year":"2017","journal-title":"J Am Pharm Assoc (2003)"},{"key":"pone.0283369.ref027","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.18549\/PharmPract.2019.3.1509","article-title":"Resident physicians\u2019 perceptions of ambulatory care pharmacy","volume":"17","author":"AH Meredith","year":"2019","journal-title":"Pharm Pract (Granada)"},{"key":"pone.0283369.ref028","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"HV Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"pone.0283369.ref029","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users.","volume":"6","author":"JD Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"pone.0283369.ref030","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"D Sullivan","year":"2012","journal-title":"Jama"},{"key":"pone.0283369.ref031","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"E Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"pone.0283369.ref032","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"PM Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"pone.0283369.ref033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsha.2018.08.003","article-title":"Comparison of the application of treatment Panel III and American College of Cardiology\/American heart Association guidelines for blood cholesterol treatment in Saudi Arabia","volume":"30","author":"S Aburuz","year":"2018","journal-title":"J Saudi Heart Assoc"},{"key":"pone.0283369.ref034","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"CP Cannon","year":"2015","journal-title":"N Engl J Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T13:30:21Z","timestamp":1679923821000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0283369"}},"subtitle":[],"editor":[{"given":"Daisaku","family":"Masuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0283369","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]}}}